Needham downgraded Cidara Therapeutics (CDTX) to Hold from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX: